Fludrocortisone
- Generic Name
- Fludrocortisone
- Brand Names
- Florinef
- Drug Type
- Small Molecule
- Chemical Formula
- C21H29FO5
- CAS Number
- 127-31-1
- Unique Ingredient Identifier
- U0476M545B
- Background
Fludrocortisone is a synthetic mineralocorticoid used in conjunction with hydrocortisone to replace missing endogenous corticosteroids in patients with adrenal insufficiency. It is functionally similar to aldosterone, the body's primary endogenous mineralocorticoid, and is structurally analogous to cortisol, differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency.
- Indication
Fludrocortisone is indicated as partial replacement therapy for primary or secondary adrenocortical insufficiency in Addison's disease. It is also indicated for the treatment of salt-losing androgenital syndrome.
- Associated Conditions
- Otitis Externa, Otitis Media (OM), Primary adrenocortical insufficiency, Secondary adrenocortical insufficiency, Salt-losing Androgenital syndrome
Effects of Fludrocortisone and Hydrocortisone in Healthy Volunteers With Aldosterone Induced Suppression
- Conditions
- Renin Angiotensin
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2012-03-02
- Lead Sponsor
- Rennes University Hospital
- Target Recruit Count
- 13
- Registration Number
- NCT00673270
- Locations
- 🇫🇷
Unité d'Investigation Clinique - Hôpital de Pontchaillou, Rennes, France
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 99
- Registration Number
- NCT00623766
- Locations
- 🇺🇸
The Angeles Clinic & Research Institute, Los Angeles, California, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus
- Conditions
- Type 1 Diabetes
- Interventions
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- Vanderbilt University
- Registration Number
- NCT00608101
Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock
- Conditions
- Septic Shock
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2010-04-06
- Lead Sponsor
- University of Versailles
- Target Recruit Count
- 508
- Registration Number
- NCT00320099
- Locations
- 🇫🇷
Hôpital Jean Verdier, Bondy, France
🇫🇷Hôpital central, Nancy, France
🇫🇷Hôpital Avicenne, Bobigny, France
Mineralocorticoid Receptor in the Treatment of Severe Depression
- Conditions
- Major Depression
- First Posted Date
- 2006-02-23
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 65
- Registration Number
- NCT00295347
- Locations
- 🇩🇪
University Hospital Hamburg-Eppendorf, Hamburg, Germany
Clinical Trial for the Prevention of Vasovagal Syncope
- Conditions
- Syncope, Vasovagal, Neurally-Mediated
- Interventions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 213
- Registration Number
- NCT00118482
- Locations
- 🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada
🇨🇦St. Boniface General Hospital, Winnipeg, Manitoba, Canada
🇨🇦Queen's University, Kingston, Ontario, Canada
Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy
- Conditions
- Parkinson's DiseaseMultiple System AtrophyOrthostatic Hypotension
- First Posted Date
- 2005-02-14
- Last Posted Date
- 2005-10-20
- Lead Sponsor
- Royal Brisbane and Women's Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00103597
- Locations
- 🇦🇺
Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia
- Conditions
- Congenital Adrenal Hyperplasia (CAH)
- Interventions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Target Recruit Count
- 62
- Registration Number
- NCT00001521
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.